A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition
about
Targeting LKB1 in cancer - exposing and exploiting vulnerabilitiesInfluence of AKT on progesterone action in endometrial diseases.Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?Expression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cellsA Multi-Step miRNA-mRNA Regulatory Network Construction Approach Identifies Gene Signatures Associated with Endometrioid Endometrial Carcinoma.The double-edged sword of AMPK signaling in cancer and its therapeutic implications.LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated.The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review.Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice.Traditional Approaches to Molecular Genetic Analysis.Endometrial Carcinoma: Specific Targeted Pathways.LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies.Cross-cancer profiling of molecular alterations within the human autophagy interaction network.The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategiesThe regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors.PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.Modeling Endometrial Cancer: Past, Present, and Future
P2860
Q26801412-055FE153-E9F3-4619-A930-B8DDA4C0E2F7Q35617565-AA213B52-19CA-4D4A-8F02-7A8C0DE577C1Q35813290-0BC5A5E9-2E3F-4AB8-A590-CFF216CE2CB5Q36459906-F5C52F99-28EC-4E7A-BB64-05532FB3F06CQ37057208-D204687E-F4ED-41B5-8443-FC088AE8B693Q38313164-79A5D132-3593-4A32-9686-3BD922525947Q38354509-8D3CE418-DC2C-4809-B153-4DB6D46F7785Q38362213-53809FB4-2594-4A9E-B353-1E928F7A7C79Q38578489-1E1C310C-3336-4318-B662-9D628AE11B8CQ39026764-2556C1C2-3A5D-4431-82A6-D17CC80BE28FQ39026766-A4A86E0F-068E-488C-A6B6-804F34051840Q39026772-3479B66D-387A-48AC-935F-E96583EF21AEQ40698951-89A6A6C9-FA80-4578-BF1A-70D300850A8AQ42320718-9F3B0886-E18D-408F-BB26-A01AD7E6ABCEQ47103987-1FFAF5B6-E2EF-4F66-99C7-7D1D11C5BCABQ47748552-6A406B80-74AA-41C2-A254-22C85441CB9FQ57170070-CED205E6-8411-4BF2-87E7-BD55290E6E74
P2860
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A genetic mouse model of invas ...... responsive to mTOR inhibition
@en
A genetic mouse model of invas ...... responsive to mTOR inhibition.
@nl
type
label
A genetic mouse model of invas ...... responsive to mTOR inhibition
@en
A genetic mouse model of invas ...... responsive to mTOR inhibition.
@nl
prefLabel
A genetic mouse model of invas ...... responsive to mTOR inhibition
@en
A genetic mouse model of invas ...... responsive to mTOR inhibition.
@nl
P2093
P2860
P1433
P1476
A genetic mouse model of invas ...... responsive to mTOR inhibition
@en
P2093
Andrea P Myers
Carolynn E Ohlson
Emmanuelle Di Tomaso
Gordon B Mills
Hailing Cheng
Jean J Zhao
Lynn Symonds
P2860
P356
10.1158/0008-5472.CAN-13-0544
P407
P577
2013-12-09T00:00:00Z